Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients

BMC Cancer

Volumn 11, Issue , 2011, Pages

  De Cremoux, Patricia ^a   Valet, Fabien ^a,b   Gentien, David ^a   Lehmann Che, Jacqueline ^c   Scott, Véronique ^d   Tran Perennou, Carine ^a   Barbaroux, Catherine ^a   Servant, Nicolas ^b   Vacher, Sophie ^a   Sigal Zafrani, Brigitte ^a   Mathieu, Marie Christine ^d   Bertheau, Philippe ^c   Guinebretière, Jean Marc ^a   Asselain, Bernard ^a,b   Marty, Michel ^c   Spyratos, Frédérique ^a  

^a INSTITUT CURIE   (France)

^b INSERM U900   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Breast cancer; Neoadjuvant setting; Quality criteria; RT qPCR; Transcriptome

Indexed keywords

BETA ACTIN; BETA GLUCURONIDASE; CELECOXIB; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN RPLPO; RIBOSOME PROTEIN; RNA; TATA BINDING PROTEIN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACCURACY; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CALIBRATION; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; FEASIBILITY STUDY; GENE TARGETING; HUMAN; HUMAN TISSUE; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PROSPECTIVE STUDY; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRANSCRIPTOMICS; TRIPLE NEGATIVE BREAST CANCER; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CLINICAL TRIAL; CLUSTER ANALYSIS; CONTROLLED CLINICAL TRIAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOADJUVANT THERAPY; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79957634906     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-215     Document Type: Article

References (31)

1. Fisher B, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998, 16(8):2672-85.
2. van der Hage JA, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001, 19(22):4224-37.
3. Pierga JY, et al. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010, 122(2):429-37. 10.1007/s10549-010-0939-3, 20480225.
4. Chevallier B, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993, 16(3):223-8. 10.1097/00000421-199306000-00006, 8338056.
5. Shi L, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006, 24(9):1151-61. 10.1038/nbt1239, 16964229.
6. Bieche I, et al. The CGA gene as new predictor of the response to endocrine therapy in ER alpha-positive postmenopausal breast cancer patients. Oncogene 2001, 20(47):6955-9. 10.1038/sj.onc.1204739, 11687975.
7. de Cremoux P, et al. Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr Relat Cancer 2004, 11(3):489-95. 10.1677/erc.1.00808, 15369450.
8. de Cremoux P, et al. Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 2007, 48(3):311-7. 10.1002/pbc.20853, 16609945.
9. Wu Z, et al. Model-Based Background Adjustment for Oligonucleotide Expression Arrays. Journal of the American statistical Association 2004, 99(468):909-17.
10. Team, R.D.C R: A Language and Environment for Statistical Computing. 2009, R Foundation for Statistical Computing, Team, R.D.C.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-10. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
12. Korde LA, et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res Treat 2010, 119(3):685-99. 10.1007/s10549-009-0651-3, 20012355.
13. Lee JK, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 2010, 16(2):711-8. 10.1158/1078-0432.CCR-09-2247, 2807997, 20068086.
14. Liedtke C, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol 2009, 27(19):3185-91. 10.1200/JCO.2008.18.5934, 2716940, 19364972.
15. Lin Y, et al. A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy. Breast Cancer Res Treat 2010, 123(3):691-9. 10.1007/s10549-009-0664-y, 19967557.
16. Bonnefoi H, et al. Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic?. Eur J Cancer 2009, 45(10):1733-43. 10.1016/j.ejca.2009.04.036, 19477634.
17. Bonnefoi H, et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007, 8(12):1071-8. 10.1016/S1470-2045(07)70345-5, 18024211.
18. Farmer P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009, 15(1):68-74. 10.1038/nm.1908, 19122658.
19. Rody A, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 2007, 16(1):86-93. 10.1016/j.breast.2006.06.008, 17010609.
20. Dumur CI, et al. Evaluation of quality-control criteria for microarray gene expression analysis. Clin Chem 2004, 50(11):1994-2002. 10.1373/clinchem.2004.033225, 15364885.
21. Imbeaud S, et al. Towards standardization of RNA quality assessment using user-independent classifiers of microcapillary electrophoresis traces. Nucleic Acids Res 2005, 33(6):56. 10.1093/nar/gni054, 546133, 15640445.
22. Raman T, et al. Quality control in microarray assessment of gene expression in human airway epithelium. BMC Genomics 2009, 10:493. 10.1186/1471-2164-10-493, 2774870, 19852842.
23. Schroeder A, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006, 7:3. 10.1186/1471-2199-7-3, 1413964, 16448564.
24. Strand C, et al. RNA quality in frozen breast cancer samples and the influence on gene expression analysis--a comparison of three evaluation methods using microcapillary electrophoresis traces. BMC Mol Biol 2007, 8:38. 10.1186/1471-2199-8-38, 1891312, 17519006.
25. Mook S, et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur J Cancer 2009, 45(7):1201-8. 10.1016/j.ejca.2009.01.004, 19232484.
26. Perou CM, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-52. 10.1038/35021093, 10963602.
27. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8(1):118-27.
28. Becker C, et al. mRNA and microRNA quality control for RT-qPCR analysis. Methods 2010, 50(4):237-43. 10.1016/j.ymeth.2010.01.010, 20079844.
29. Fleige S, Pfaffl MW. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 2006, 27(2-3):126-39. 10.1016/j.mam.2005.12.003, 16469371.
30. Murphy J, Bustin SA. Reliability of real-time reverse-transcription PCR in clinical diagnostics: gold standard or substandard?. Expert Rev Mol Diagn 2009, 9(2):187-97. 10.1586/14737159.9.2.187, 19298142.
31. Taylor S, et al. A practical approach to RT-qPCR-Publishing data that conform to the MIQE guidelines. Methods 2010, 50(4):S1-5. 10.1016/j.ymeth.2010.01.005, 20215014.